First-Line Treatment of Newly Diagnosed Pleural Mesothelioma with Epithelioid Histology
This protocol addresses systemic treatment selection for patients with newly diagnosed pleural mesothelioma in whom the epithelioid histologic subtype has been confirmed — the classification that determines which first-line options are indicated.
Clinical Scenario
Newly diagnosed pleural mesothelioma with confirmed epithelioid histologic subtype. Histology confirmation is a key determinant of appropriate first-line systemic therapy in this setting.
Treatment Approach
First-line systemic therapy for this population includes immunotherapy-based regimens. The full protocol covers the available evidence-based options and the clinical factors that guide selection among them — the complete structured regimen is accessible below.
Treatment Goal
Stable or responding disease — absence of disease progression.
References
DOI: 10.1200/JCO-24-02425
- In patients with newly diagnosed epithelioid mesothelioma, ipilimumab plus nivolumab immunotherapy should be offered as a first-line systemic treatment option.
- Ipilimumab plus nivolumab immunotherapy should be administered for a duration up to 2 years in the absence of disease progression or intolerable toxicity.
- In patients with epithelioid histology, pemetrexed plus platinum-based chemotherapy with or without bevacizumab may be offered as a first-line systemic treatment option.
View source ↗